Major Milestone: Inura Medical Closes Pre-series A Financing Round

We are delighted to announce today the closing of the Pre-Series A Financing Round at Inura Medical. Our mission is to improve women’s health through the development of an urethral ovulum for the treatment of patients suffering from urinary bladder diseases. Thus, our first pharmaceutical product is addressing an unmet medical need in overactive bladder (OAB).


Basel, Switzerland, May 20, 2021.

The investment proceeds from this round will be used to continue business development and finalize the pre-clinical work. The pre-clinical trials in dogs started this month, and the First-In-Human study preparations are ongoing.

This financing round was a major milestone for our team. It brings us a step closer to the realization of our dream of helping patients with OAB. The funds raised will enable us to continue with our development program”, says CMO of Inura, Dr. Rafiq Hussain.

To upscale our business development, Inura has recently participated in the following programs and accelerators: inQbator’s Ignite Program, Swiss Innovation Challenge, Swiss Healthcare Start-ups Booster Program and “100 fürs Baselbiet” sponsored by BLKB.

Inura Medical has developed a product that has all the ingredients to change the rules of the game in OAB treatment. I’m very proud to participate in the further development of the company and thereby contribute to improving patients’ lives”, remarked Vanja Ivancevic, CEO of Inura Medical.

Inura’s novel product has the potential to revolutionize the quality of life of patients suffering from OAB and dramatically change the way they cope with their health disorder and gain back control of their lives.

About Inura Medical

Inura Medical AG (“Inura”) is a Swiss start-up company with a clear vision to make a difference in women’s health. Inura’s product is an innovative, first-of-a-kind “urethral ovulum” that utilizes a novel route of drug administration to treat diseases of the bladder and lower urinary tract. Inura’s technology results from decades of work in urology by Professor Grant S. Mulholland, a renowned surgeon, academic, and past President of the American Urology Association. The first indication we are addressing with the ovulum is a chronic disease, named overactive bladder (OAB). More details on